Navigation Links
Boston IVF is First in Northeast to Offer Pioneering Test of Women's Biological Clock
Date:1/21/2008

Repromedix's Plan Ahead(TM) Test Offers Most Accurate Measurement of

Women's Ovarian Reserve

WALTHAM, Mass., Jan. 21 /PRNewswire/ -- Boston IVF today announced it will be the first IVF center in the northeast to offer Repromedix's Plan Ahead(TM) test, an innovative blood test that provides an assessment of a woman's egg supply by combining multiple factors including the measurement of ovary-related hormones AMH, Inhibin B, and FSH. The window of opportunity for a woman to have children by natural conception is dependent upon an adequate supply of eggs which inevitably declines as a woman ages and her "biological clock ticks." Plan Ahead enables a woman to compare her estimated egg supply with the normal range expected for women of the same age.

The Plan Ahead Report provides valuable directional information to women planning to have children after their late twenties. Women with faster biological clocks should seek further advice from fertility experts to help ensure that they can have the families they were hoping for.

Dr. Michael M. Alper, Harvard Medical School professor, and the medical director and co-founder of Boston IVF, an internationally renowned fertility treatment center, commented, "As more and more women delay pregnancy until their 30s and even their 40s, there is an urgent need for an accurate early assessment of their fertility. Unfortunately, we see far too many women late in the process when time is of the essence. The fertility field has been waiting for a test like this, and we are delighted to be the first practice to partner with Repromedix in providing this innovative test to women in the greater Boston area."

"The Plan Ahead test represents an extraordinary advance in fertility diagnostics compared to what has been readily available to the general population," said Dr. Benjamin Leader, Chief Medical Officer, Repromedix Corp. "Many fertility experts view the gold standard of egg supply measurement to be the number of eggs obtained through egg retrieval, an expensive procedure reserved for specialty fertility clinics involving hormone injections and a minimally invasive procedure. The Plan Ahead test offers similar information to the general public via a simple blood test."

Repromedix Corp., the Plan Ahead test co-developer and leading national diagnostic laboratory for fertility testing, chose Boston IVF to be one of a select number of IVF centers to debut the test. Repromedix will expand the Plan Ahead test launch to major markets across the United States throughout 2008.

Plan Ahead is now available to women in the greater Boston area, and women interested in the Plan Ahead test can purchase a test online at http://www.planaheadtest.com/us or at Boston IVF, where they can also have their blood drawn. The blood sample is sent to Repromedix, whose lab performs the advanced testing and submits the report and recommendations to the patient's physician. The cost of the Plan Ahead test is $350.

Women interested in learning more about Plan Ahead, should visit: http://www.planaheadtest.com/us.

About Boston IVF (http://www.bostonivf.com)

Established in 1986, Boston IVF is one of America's most successful fertility centers. Using a team approach to meet every aspect of patients' needs, Boston IVF is committed to giving everyone the chance to build a family. Boston IVF provides patients with unparalleled medical care and the best experience with the expertise of premier doctors and professional staff, who are affiliated with Harvard Medical School. It is world renowned for its highly successful and innovative infertility treatments, highest quality service, state-of-the-art methods, ongoing scientific research, and on-site complementary healthcare at its Domar Center. Boston IVF has convenient locations in Waltham, Mass., Brookline, Mass., and Quincy, Mass., and its doctors see patients at leading hospitals throughout Mass. and Maine.

About Repromedix (http://www.repromedix.com)

Repromedix is the leading national diagnostic laboratory for fertility testing and offers a multifaceted approach to clinical fertility testing that encompasses many medical disciplines including endocrinology, immunology and genetics. Repromedix offers the most comprehensive suite of advanced diagnostic tests that provide valuable information regarding the complex problems of reproductive failure. Since its inception in 1993, the company has assisted more than 45,000 patients by performing over 100,000 diagnostic tests for recurrent pregnancy loss, premature ovarian failure, male infertility, and unexplained infertility. Repromedix is a portfolio company of Brook Venture Partners, Ironwood Capital Management, and Brooke Private Equity Advisors.

Media contact: Julie Dennehy

508-533-8311 or julie@dennehypr.com


'/>"/>
SOURCE Repromedix
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Childrens Hospital Boston Mourns the Death of Dr. Judah Folkman, World Renowned Researcher and Founder of the Field of Angiogenesis
2. Boston Scientific Announces Court Decision
3. Boston Scientific to Participate in JP Morgan Health Care Conference
4. Boston Scientific Announces CE Mark Approval for Next-Generation Cardiac Resynchronization Therapy Defibrillator
5. Boston Scientific Agrees To Sell Fluid Management and Venous Access Businesses to Avista Capital Partners for $425 Million
6. Boston University Medical Center researcher honored
7. ESi Announces Strategic New Hire in Boston
8. Boston Scientific Welcomes FDA Panel Recommendation to Approve PROMUS(TM) / XIENCE(TM) V Everolimus-eluting Coronary Stent System
9. Boston Scientific to Participate in BMO Capital Markets Healthcare Conference
10. Boston University School of Medicine Professor receives award from American Heart Association
11. Boston Scientific Announces Amended Agreement to Settle Product Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... ... ... Dr. Ronald E. Hawkins, vice president for academic affairs ... Bell, DO, MBA, HPF, FACOEP-dist., FACEP, as the new dean of Liberty ... to Liberty from the Ohio University Heritage College of Osteopathic Medicine (OU-HCOM), where ...
(Date:2/24/2017)... ... February 24, 2017 , ... The narrative in “ Signal 8: ... ’s true account of his paramedic experiences. Schanssema describes the tragedies he saw, as ... attempts to overcome them. , Schanssema, initially unsure of the career path he wanted ...
(Date:2/24/2017)... ... , ... Indiana Fiber Network (IFN) President and CEO Kelly C. Dyer recently ... as the Chairman of the Management Committee when IFN was originally formed in 2002 ... of investor/owners and development of the business plan. He became the first paid ...
(Date:2/23/2017)... ... February 23, 2017 , ... Thinksport, the most ... Jensie Gran Fondo of Marin. For the second year in a row, cyclists ... sunscreen. , “We are thrilled to provide our safe, non-toxic sunscreen to over ...
(Date:2/23/2017)... ... February 23, 2017 , ... The American Cleft Palate-Craniofacial Association (ACPA) is pleased ... KLS is a longtime supporter of the event. , "We are pleased that KLS ... Dr. Bob Havlik, 2017 ACPA President. "KLS Martin has a long track record of ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Feb. 24, 2017 Zimmer Biomet Holdings, Inc. ... healthcare, will present at the Cowen and Company 37 ... Marriott Copley Place on Tuesday, March 7, 2017 at ... webcast of the presentation can be accessed at ... following the conference via Zimmer Biomet,s Investor Relations website ...
(Date:2/24/2017)... , Feb. 24, 2017  In conjunction with ... 2016 financial results press release, you are invited to ... live over the internet on Tuesday, March 14, 2017 ... A live audio webcast of the presentation ... www.durect.com and clicking "Investor Relations."  If you are ...
(Date:2/24/2017)... 24. Februar 2017 ITL Limited, ( ... Gesundheitsbereiches, ist erfreut, für das zum 31. Dezember ... Vorjahreszeitraum exzellente Ergebnisse vorlegen zu können. Eine vollständige ... Wachstum" finden Sie hier . ... Steuern 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
Breaking Medicine Technology: